Next-Generation Glaucoma Therapy

Delivering Effective, Safe, & Longer-Term Treatment

 
 
ophthalmology-U489JNG.jpg

The Technology

 

Glaucoma is the leading cause of irreversible blindness worldwide, yet current treatment options are suboptimal for patients and providers.

ELT (Excimer Laser Trabeculotomy) micro-invasive glaucoma surgery was first used clinically in 1997 - and is absolutely implant free.

 

 
Open-Angle Glaucoma

Open-Angle Glaucoma

ELT-Created Channels in Schlemm’s Canal

ELT-Created Channels in Schlemm’s Canal

ELT-Created Channels in Schlemm’s Canal

ELT-Created Channels in Schlemm’s Canal

 
 

ELT treats the pathology leading to open-angle glaucoma exactly where it occurs by considerably increasing the permeability of the trabecular meshwork, with lower risks than other treatment methods.

 
 

The Facts

 
 
  • ELT is a simple out-patient procedure completed in < 10 minutes.

  • ELT Technology creates microscopic channels via a non-thermal laser, without scarring.

  • ELT reduces intraocular pressure (IOP), a crucial intervention that aims to prevent the devastating effects of glaucoma progression.

  • Daily eye drops have low compliance & tolerability.

  • ELT is safe & effective, with market-leading clinical outcomes.

  • ELT shows 75% improvement in visual acuity and sustained IOP reduction for at least 5 years.

 
 

TREATMENT REIMAGINED.

ELT is next-generation treatment, positioned to disrupt the medical industry.

 
ophthalmology-examination-with-magnifying-glass-RVTPSZE.jpg
 
ELT Sight
  • > 38% IOP Reduction

  • 75% Corrected Visual Acuity Improvement

  • 50% Medication Reduction

ELT Sight
  • ELT Sight < 10 Minutes Per Procedure

  • Easily Combined with Cataract Surgery

 
 
 

CLINICAL STUDIES

 
AdobeStock_220944187.jpeg
 
Capture-1 copy.png

Regulatory Status
CE-Mark obtained in 2014, permits commercialization throughout European Union; not currently approved for U.S. sales or by FDA (anticipated trial 2019).

Clinical Impact
Extensive clinical experience to date, demonstrated IOP reduction at up to 5-8 year follow up.

Novel Mechanism Delivers Impactful Clinical Results  .png

Clinical Opportunity
> 20% of cataract surgeries are performed on patients with glaucoma; ELT can be completed with or without cataract surgery.

 
 
 

ABOUT

 
eyesight-exam-in-clinic-with-asian-doctor-and-PRBFRT5.jpg
 

 Technology Specialists

We are a globally leading supplier of UV-light medical and industrial products. Since former members of TuiLaser AG founded MLase in December 2007, we have dedicated ourselves to developing and producing innovative and high-quality laser and light systems, the result of many years’ experience garnered by a team of highly specialized experts.

MLase AG provides their customers with top quality products, taking into consideration the latest technological aspects. At MLase, we consider ourselves your direct contact for any questions regarding our products. That is why we place great value in a close dialogue with our customers.

 
 

CONTACT

 
an-elderly-patient-meeting-doctor-at-the-hospital-PDHAVKC.jpg

Management Team

Elliot Friedman, MSMS
Chief Executive Officer
elliotf@eltsight.com

Markus Enders, CFO
Markus.Enders@mlase.com

Johannes Junger, CTO
Johannes.Junger@mlase.com

Matilda Parente, MD, FCAP
Chief Medical Officer
matildap@eltsight.com

Oded Ben-Joseph, PhD, MBA
Member, Board of Directors
odedb@eltsight.com

Axel Werbach 
Vice President, International Sales
axel.werbach@mlase.com

Scientific Advisory Board

Ike K. Ahmed, MD, FRCSC

Antonio M. Fea, MD, PhD

Richard A. Lewis, MD

Antonio Moreno Valladares, MD, PhD

Thomas F. Neuhann, MD

Name *
Name